Zobrazeno 1 - 10
of 775
pro vyhledávání: '"Bafaloukos, D."'
Autor:
Bafaloukos, D., Molfeta, A., Gazouli, I., Chatzichristou, E., Bousboukea, A., Tarampikou, A., Giorgali, A., Saridaki, Z., Samonis, G.
Publikováno v:
In EJC Skin Cancer 2024 2 Supplement 1
Autor:
Linardou, H., Kosmidis, T., Papadopoulou, K., Korfiatis, N., Vozikis, A., Lampaki, S., Psyrri, A., Fountzilas, E., Christopoulou, A.N., Samantas, E., Vagionas, A., Mountzios, G., Goumas, G., Tsoukalas, N.G., Athanasiadis, I., Bafaloukos, D., Panopoulos, C.G., Koufaki, M.I., Fountzilas, G., Kosmidis, P.A.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S863-S864
Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records of patients with cancer a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::60b68396854ba135951a4a2886c6c74c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999633
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999633
Background: Dose-dense sequential chemotherapy with anthracyclines and taxanes achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal chemotherapy schedule and interval between cycles remain under investigation. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::b887f87ae91ffb8c17dfc2d8d8010f9c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220693
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3220693
Autor:
Kosmidis, P.A. *, Fountzilas, G., Eleftheraki, A.G., Kalofonos, H.P., Pentheroudakis, G., Skarlos, D., Dimopoulos, M.A., Bafaloukos, D., Pectasides, D., Samantas, E., Boukovinas, J., Lambaki, S., Katirtzoglou, N., Bakogiannis, C., Syrigos, K.N.
Publikováno v:
In Annals of Oncology April 2011 22(4):827-834
Publikováno v:
In Annals of Oncology March 2011 22(3):545-552
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generation irreversible EGFR-TKI, ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::8d1170e1561e5624975a5832e29d2e7b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103031
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103031
The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable longterm efficacy in patients with BRAF V600–mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2c6a793714c09337d046dc22350ec580
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102420
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102420